Ares Genetics GmbH

16 articles about Ares Genetics GmbH

• OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

  8/7/2023

  OpGen, Inc. announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.

• OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

  6/26/2023

  OpGen, Inc. and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.

• OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth

  3/1/2023

  OpGen, Inc. and its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, announced completion of its move from the incubator space at the Vienna Bio Center into a brand new and tailored state of the art facility at the Abundance Gate in Vienna, Austria.

• OpGen subsidiary Ares Genetics announces granting of key patent in China

  1/26/2023

  OpGen, Inc. and OpGen subsidiary, Ares Genetics (Ares) announced today the granting of a key patent by the China National Intellectual Property Administration (CNIPA).

• OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven

  7/26/2022

  OpGen, Inc. announced today that its subsidiary Ares Genetics GmbH (Ares Genetics) and the Belgian National Reference Centre have entered into a collaboration agreement to jointly evaluate computational tools developed by Ares Genetics for the identification and characterization of Streptococcus pneumoniae for diagnostic purposes.

• OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

  4/6/2022

  OpGen, Inc. announced that its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, is expanding its strategic collaboration with Sandoz, aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance, and to that end has extended its collaboration agreement until January 31, 2025.

• 

  Novartis Augments Transformational Week with US Approval, European Milestones

  4/6/2022

  With the accelerated approval from the U.S. Food and Drug Administration, Vijoice becomes the first treatment approved in the United States for PROS

• OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

  12/14/2021

  Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogens ARESdb contents has grown by more than 40% in a year.

• OpGen Subsidiary Ares Genetics Launches AREScloud

  10/21/2021

  OpGen, Inc today announced that its subsidiary Ares Genetics has commercially launched its AREScloud web application.

• OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars

  6/9/2021

  OpGen, Inc. announced that its subsidiary Ares Genetics, which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance, is developing a culture-free, genomic assay for comprehensive AMR surveillance.

• OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing

  2/16/2021

  Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data

• OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud

  10/5/2020

  Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions ares-genetics.cloud for AI-powered Antibiotic Resistance Prediction awarded by Federal Ministry for Digital and Economic Affairs VIENNA, Austria, and GAITHERSBURG, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has won the Austrian Digitization Award. Ares Genetics has been selected by an

• OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test

  9/8/2020

  OpGen, Inc., announced that its subsidiary Ares Genetics GmbH has been nominated for the 40th Austrian Innovation Award.

• OpGen Group Company Ares Genetics Demonstrates Feasibility of CLIA-compliant Next Generation Sequencing Workflow for Identification of Bacterial Pathogens and Antibiotic Resistance Markers

  8/11/2020

  Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database Pathogens correctly identified with 100% sensitivity and specificity, antibiotic resistance markers with >95% sensitivity and >99% specificity, respectively Study paves the way for routine clinical diagnostic application of next-generation sequencing (NGS) in timely as well as accurate infectious disease testing and drug

• QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

  2/18/2019

  Developing Sample to Insight solutions to accelerate research on growing public health threat

• Ares Genetics GmbH Release: Company News: "GEAR – Predicting Antibiotic Resistances With Genetic Data" Succeeds In Competition “Landmarks In The Land Of Ideas”

  6/26/2017